バイオ医薬品受託製造の世界市場レポート 2025年

バイオ医薬品受託製造の市場規模は今後数年で急成長が見込まれます。2029年にはCAGR11.0％で337億5,000万米ドルに成長します。予測期間における成長の背景には、アウトソーシング動向の高まり、バイオシミラー開発、市場開拓期間の短縮要件、世界の市場拡大、専門サービスの重視などがあります。予測期間の主な動向には、技術統合、高分子以外のアウトソーシング拡大、先端製造技術の採用、品質とコンプライアンスの重視、バイオシミラー製造の台頭などがあります。

個別化医療に対する需要の高まりは、今後数年間のバイオ医薬品受託製造市場の成長を大きく後押しすると予想されます。個別化医療とは、遺伝、環境、ライフスタイルなど患者個人の特性を考慮し、治療効果や治療成績を向上させるオーダーメイドのヘルスケアアプローチを意味します。ゲノミクスの進歩、患者のエンパワーメントの向上、治療効果の向上など、いくつかの要因が個別化医療の需要を促進しています。受託製造業者は、個別化治療特有のニーズを満たすカスタマイズされた製造プロセスを開発することができ、小ロットサイズや独自の製剤に対応することができます。例えば、米国を拠点とする非営利団体である個別化医療連合（Personalized Medicine Coalition）の報告書によると、2024年2月、FDAは希少疾患患者向けに16の新規個別化療法を承認したが、2022年にはわずか6つでした。その結果、個別化医療に対する需要の高まりが、バイオ医薬品受託製造市場の成長に拍車をかけています。

バイオ医薬品受託製造市場の成長軌道は、臨床試験の増加に強く影響されています。医療介入を評価するために重要なこれらの臨床試験は、バイオ医薬品受託製造が促進する治験薬の効率的な生産と供給に依存しています。2023年5月にXtalksが示したように、ClinicalTrials.govに登録された臨床試験は世界的に大幅に増加しており、2021年初頭の365,000件以上から大幅に増加し、452,604件に達しています。したがって、臨床試験の急増はバイオ医薬品受託製造市場を直接後押しします。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、コロナ禍、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界バイオ医薬品受託製造PESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界のバイオ医薬品受託製造市場：成長率分析
• 世界のバイオ医薬品受託製造市場の実績：規模と成長, 2019-2024
• 世界のバイオ医薬品受託製造市場の予測：規模と成長, 2024-2029, 2034F
• 世界バイオ医薬品受託製造総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界のバイオ医薬品受託製造市場：製品別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 生物学的製剤
• モノクローナル抗体（MAB）
• 組み換えタンパク質
• ワクチン
• アンチセンス、RNAi、分子療法
• バイオシミラー
• 世界のバイオ医薬品受託製造市場：ソース別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 哺乳類
• 非哺乳類
• 世界のバイオ医薬品受託製造市場：サービス別、実績と予測, 2019-2024, 2024-2029F, 2034F
• プロセス開発
• 充填および仕上げ作業
• 分析および品質管理研究
• パッケージ
• 世界のバイオ医薬品受託製造市場：用途別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 臨床
• 商業用
• 世界のバイオ医薬品受託製造市場、生物製剤の種類別のサブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 酵素
• ホルモン
• 抗体
• 世界のバイオ医薬品受託製造市場モノクローナル抗体（MAB）の種類別のサブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• ヒトMAB
• キメラMAB
• マウスモノクローナル抗体
• 世界のバイオ医薬品受託製造市場、組み換えタンパク質の種類別のサブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• インスリン
• 成長因子
• サイトカイン
• 世界のバイオ医薬品受託製造市場、ワクチンの種類別のサブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 生弱毒化ワクチン
• 不活化ワクチン
• サブユニットワクチン
• 世界のバイオ医薬品受託製造市場アンチセンス、RNAi、分子療法の種類別のサブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• アンチセンスオリゴヌクレオチド
• RNA干渉製品
• 遺伝子治療
• 世界のバイオ医薬品受託製造市場、バイオシミラーのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• バイオシミラーモノクローナル抗体
• バイオシミラーインスリン
• バイオシミラー成長ホルモン

第7章 地域別・国別分析

• 世界のバイオ医薬品受託製造市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界のバイオ医薬品受託製造市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• バイオ医薬品受託製造市場：競合情勢
• バイオ医薬品受託製造市場：企業プロファイル
  • Boehringer Ingelheim GmbH Overview, Products and Services, Strategy and Financial Analysis
  • Lonza Group Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • Inno Biologics Sdn Bhd Overview, Products and Services, Strategy and Financial Analysis
  • Rentschler Biopharma SE Overview, Products and Services, Strategy and Financial Analysis
  • Samsung Biologics Co. Ltd. Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• AGC Biologics
• ProBioGen AG
• FUJIFILM Diosynth Biotechnologies
• Thermo Fisher Scientific Inc.
• Binex Co. Ltd.
• AbbVie Inc.
• Catalent Inc.
• Pfizer Inc.
• Merck KGaA
• Pressure BioSciences
• Novartis International AG
• Cambrex Corporation
• Emergent BioSolutions Inc.
• JRS Pharma GmbH & Co. KG
• WuXi Biologics

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• バイオ医薬品受託製造市場2029：新たな機会を提供する国
• バイオ医薬品受託製造市場2029：新たな機会を提供するセグメント
• バイオ医薬品受託製造市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Biopharmaceutical contract manufacturing involves a process where a biopharmaceutical company engages a third-party manufacturer to produce drugs or biologic products on its behalf. This practice is employed when pharmaceutical businesses utilize external facilities to manufacture pharmaceuticals under their brand, akin to private label or third-party production.

The primary products of biopharmaceutical contract manufacturing encompass a range of biologics, monoclonal antibodies (mABs), recombinant proteins, vaccines, antisense, mai, molecular therapy, and biosimilars. Monoclonal antibodies (MABs) are laboratory-engineered proteins designed to mimic the function of antibodies within the human body. These antibodies are derived from mammalian and non-mammalian sources. Services offered in this domain include process development, fill and finish operations, analytical and quality control studies, as well as packaging, catering to both clinical and commercial applications.

The biopharmaceutical contract manufacturing market research report is one of a series of new reports from The Business Research Company that provides biopharmaceutical contract manufacturing optical components market statistics, including biopharmaceutical contract manufacturing optical components industry global market size, regional shares, competitors with a biopharmaceutical contract manufacturing optical components market share, detailed biopharmaceutical contract manufacturing optical components market segments, market trends and opportunities, and any further data you may need to thrive in the biopharmaceutical contract manufacturing optical components industry. This biopharmaceutical contract manufacturing optical components market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The biopharmaceuticals contract manufacturing market size has grown rapidly in recent years. It will grow from$20.13 billion in 2024 to $22.21 billion in 2025 at a compound annual growth rate (CAGR) of 10.3%. The growth in the historic period can be attributed to increased biopharmaceutical development, cost efficiency and risk mitigation, growing pipeline of biologics, globalization of biopharmaceutical industry, flexible manufacturing solutions

The biopharmaceuticals contract manufacturing market size is expected to see rapid growth in the next few years. It will grow to $33.75 billion in 2029 at a compound annual growth rate (CAGR) of 11.0%. The growth in the forecast period can be attributed to increasing outsourcing trends, biosimilar development, shorter time-to-market requirements, global market expansion, focus on specialized services. Major trends in the forecast period include technological integration, outsourcing expansion beyond large molecules, advanced manufacturing technologies adoption, focus on quality and compliance, rise of biosimilars manufacturing,.

The rising demand for personalized medicine is anticipated to significantly boost the growth of the biopharmaceutical contract manufacturing market in the coming years. Personalized medicine represents a tailored healthcare approach that considers individual patient characteristics, such as genetics, environment, and lifestyle, to improve treatment effectiveness and outcomes. Several factors are driving the demand for personalized medicine, including advancements in genomics, increased patient empowerment, and enhanced treatment efficacy. Contract manufacturers are able to develop customized production processes that meet the specific needs of personalized therapies, accommodating small batch sizes and unique formulations. For example, a report from the Personalized Medicine Coalition, a U.S.-based non-profit organization, noted that in February 2024, the FDA approved 16 new personalized therapies for patients with rare diseases in 2023, compared to just six in 2022. Consequently, the increasing demand for personalized medicine is fueling the growth of the biopharmaceutical contract manufacturing market.

The growth trajectory of the biopharmaceuticals contract manufacturing market is strongly influenced by the increasing number of clinical trials. These trials, crucial for assessing medical interventions, rely on efficient production and supply of investigational drugs facilitated by biopharmaceutical contract manufacturing. As indicated by Xtalks in May 2023, there has been a substantial rise in registered clinical trials globally on ClinicalTrials.gov, reaching 452,604, a significant increase from early 2021's over 365,000. Hence, the upsurge in clinical trials directly propels the biopharmaceuticals contract manufacturing market.

A prominent trend shaping the biopharmaceuticals contract manufacturing market is product innovation. Major industry players are investing in innovative products to maintain their market position. An example is the strategic contract manufacturing agreement between Thermo Fisher Scientific and Elektrofi in February 2023. This collaboration aims to support the commercial production of Elektrofi's pioneering ultra-high concentration subcutaneous products using innovative microparticle technology. This advancement allows patients to self-administer biologics at home, revolutionizing the delivery of crucial medications.

A significant focus within the biopharmaceutical contract manufacturing market is the development of monoclonal antibodies using advanced platforms such as the go-to cell line platform. KBI Biopharma Inc's launch of SUREmAb in September 2023 exemplifies this focus. Leveraging KBI's SUREtechnology Platform, SUREmAb streamlines processes, enabling swift research cell bank development and a rapid transition from DNA to GMP drug substance. The collaboration between KBI Biopharma and Selexis contributed to this operational optimization, enhancing monoclonal antibody development.

In June 2022, Asahi Kasei Medical Co. Ltd., a chemical company based in Japan, successfully acquired Bionova Scientific, LLC, for an undisclosed sum. This strategic acquisition enables Asahi Kasei Medical to broaden its bioprocess business by integrating a biopharmaceutical Contract Development and Manufacturing Organization (CDMO), thereby expanding its reach to a more diverse customer base, including those at the forefront of developing cutting-edge next-generation biopharmaceuticals. Bionova Scientific, LLC, based in the US, specializes in providing contract process development services and Good Manufacturing Practice (GMP)-compliant contract manufacturing services to biopharmaceutical firms.

Major companies operating in the biopharmaceuticals contract manufacturing market include Boehringer Ingelheim GmbH, Lonza Group Ltd., Inno Biologics Sdn Bhd, Rentschler Biopharma SE, Samsung Biologics Co. Ltd., AGC Biologics, ProBioGen AG, FUJIFILM Diosynth Biotechnologies, Thermo Fisher Scientific Inc., Binex Co. Ltd., AbbVie Inc., Catalent Inc, Pfizer Inc., Merck KGaA, Pressure BioSciences, Novartis International AG, Cambrex Corporation, Emergent BioSolutions Inc., JRS Pharma GmbH & Co. KG, WuXi Biologics, Siegfried Holding AG, Toyobo Co. Ltd., ADMA Biologics Inc., UCB S.A., AstraZeneca PLC, Johnson & Johnson, Takeda Pharmaceutical Company Limited, Shire Pharmaceuticals LLC, Baxter International Inc., Becton Dickinson and Company, Polyphor Ltd., Patheon Inc., Alcami Corporation

North America was the largest region in the biopharmaceutical contract manufacturing market in 2024. Asia-Pacific is expected to be the fastest-growing region in the global biopharmaceuticals contract manufacturing market forecast period. The regions covered in the biopharmaceuticals contract manufacturing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the biopharmaceuticals contract manufacturing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The biopharmaceutical contract manufacturing market includes revenues earned by entities providing services such as formulation development, GMP manufacturing, and supply chain management. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Biopharmaceuticals Contract Manufacturing Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on biopharmaceuticals contract manufacturing market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for biopharmaceuticals contract manufacturing ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The biopharmaceuticals contract manufacturing market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Product: Biologics; Monoclonal Antibodies (MABs); Recombinant Proteins; Vaccines; Antisense, RNAi, And Molecular Therapy; Biosimilars
• 2) By Source: Mammalian; Non-mammalian
• 3) By Service: Process Development; Fill And Finish Operations; Analytical And QC studies; Packaging
• 4) By Application: Clinical; Commercial
• Subsegments:
• 1) By Biologics: Enzymes; Hormones; Antibodies
• 2) By Monoclonal Antibodies (MABs): Human MABs; Chimeric MABs; Murine MABs
• 3) By Recombinant Proteins: Insulin; Growth Factors; Cytokines
• 4) By Vaccines: Live Attenuated Vaccines; Inactivated Vaccines; Subunit Vaccines
• 5) By Antisense, RNAi, And Molecular Therapy: Antisense Oligonucleotides; RNA Interference Products; Gene Therapies
• 6) By Biosimilars: Biosimilar Monoclonal Antibodies; Biosimilar Insulin; Biosimilar Growth Hormones
• Companies Mentioned: Boehringer Ingelheim GmbH; Lonza Group Ltd.; Inno Biologics Sdn Bhd; Rentschler Biopharma SE; Samsung Biologics Co. Ltd.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Biopharmaceuticals Contract Manufacturing Market Characteristics

3. Biopharmaceuticals Contract Manufacturing Market Trends And Strategies

4. Biopharmaceuticals Contract Manufacturing Market - Macro Economic Scenario including the impact of Interest Rates, Inflation, Geopolitics and Covid And Recovery on the Market

5. Global Biopharmaceuticals Contract Manufacturing Growth Analysis And Strategic Analysis Framework

• 5.1. Global Biopharmaceuticals Contract Manufacturing PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Biopharmaceuticals Contract Manufacturing Market Growth Rate Analysis
• 5.4. Global Biopharmaceuticals Contract Manufacturing Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Biopharmaceuticals Contract Manufacturing Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Biopharmaceuticals Contract Manufacturing Total Addressable Market (TAM)

6. Biopharmaceuticals Contract Manufacturing Market Segmentation

• 6.1. Global Biopharmaceuticals Contract Manufacturing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Biologics
• Monoclonal Antibodies (MABs)
• Recombinant Proteins
• Vaccines
• Antisense, RNAi, And Molecular Therapy
• Biosimilars
• 6.2. Global Biopharmaceuticals Contract Manufacturing Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Mammalian
• Non-mammalian
• 6.3. Global Biopharmaceuticals Contract Manufacturing Market, Segmentation By Service, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Process Development
• Fill And Finish Operations
• Analytical And QC studies
• Packaging
• 6.4. Global Biopharmaceuticals Contract Manufacturing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Clinical
• Commercial
• 6.5. Global Biopharmaceuticals Contract Manufacturing Market, Sub-Segmentation Of Biologics, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Enzymes
• Hormones
• Antibodies
• 6.6. Global Biopharmaceuticals Contract Manufacturing Market, Sub-Segmentation Of Monoclonal Antibodies (MABs), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Human MABs
• Chimeric MABs
• Murine MABs
• 6.7. Global Biopharmaceuticals Contract Manufacturing Market, Sub-Segmentation Of Recombinant Proteins, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Insulin
• Growth Factors
• Cytokines
• 6.8. Global Biopharmaceuticals Contract Manufacturing Market, Sub-Segmentation Of Vaccines, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Live Attenuated Vaccines
• Inactivated Vaccines
• Subunit Vaccines
• 6.9. Global Biopharmaceuticals Contract Manufacturing Market, Sub-Segmentation Of Antisense, RNAi, And Molecular Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Antisense Oligonucleotides
• RNA Interference Products
• Gene Therapies
• 6.10. Global Biopharmaceuticals Contract Manufacturing Market, Sub-Segmentation Of Biosimilars, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Biosimilar Monoclonal Antibodies
• Biosimilar Insulin
• Biosimilar Growth Hormones

7. Biopharmaceuticals Contract Manufacturing Market Regional And Country Analysis

• 7.1. Global Biopharmaceuticals Contract Manufacturing Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Biopharmaceuticals Contract Manufacturing Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Biopharmaceuticals Contract Manufacturing Market

• 8.1. Asia-Pacific Biopharmaceuticals Contract Manufacturing Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Biopharmaceuticals Contract Manufacturing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Biopharmaceuticals Contract Manufacturing Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Biopharmaceuticals Contract Manufacturing Market, Segmentation By Service, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Biopharmaceuticals Contract Manufacturing Market

• 9.1. China Biopharmaceuticals Contract Manufacturing Market Overview
• 9.2. China Biopharmaceuticals Contract Manufacturing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Biopharmaceuticals Contract Manufacturing Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Biopharmaceuticals Contract Manufacturing Market, Segmentation By Service, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Biopharmaceuticals Contract Manufacturing Market

• 10.1. India Biopharmaceuticals Contract Manufacturing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Biopharmaceuticals Contract Manufacturing Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Biopharmaceuticals Contract Manufacturing Market, Segmentation By Service, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Biopharmaceuticals Contract Manufacturing Market

• 11.1. Japan Biopharmaceuticals Contract Manufacturing Market Overview
• 11.2. Japan Biopharmaceuticals Contract Manufacturing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Biopharmaceuticals Contract Manufacturing Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Biopharmaceuticals Contract Manufacturing Market, Segmentation By Service, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Biopharmaceuticals Contract Manufacturing Market

• 12.1. Australia Biopharmaceuticals Contract Manufacturing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Biopharmaceuticals Contract Manufacturing Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Biopharmaceuticals Contract Manufacturing Market, Segmentation By Service, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Biopharmaceuticals Contract Manufacturing Market

• 13.1. Indonesia Biopharmaceuticals Contract Manufacturing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Biopharmaceuticals Contract Manufacturing Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Biopharmaceuticals Contract Manufacturing Market, Segmentation By Service, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Biopharmaceuticals Contract Manufacturing Market

• 14.1. South Korea Biopharmaceuticals Contract Manufacturing Market Overview
• 14.2. South Korea Biopharmaceuticals Contract Manufacturing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Biopharmaceuticals Contract Manufacturing Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Biopharmaceuticals Contract Manufacturing Market, Segmentation By Service, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Biopharmaceuticals Contract Manufacturing Market

• 15.1. Western Europe Biopharmaceuticals Contract Manufacturing Market Overview
• 15.2. Western Europe Biopharmaceuticals Contract Manufacturing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Biopharmaceuticals Contract Manufacturing Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Biopharmaceuticals Contract Manufacturing Market, Segmentation By Service, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Biopharmaceuticals Contract Manufacturing Market

• 16.1. UK Biopharmaceuticals Contract Manufacturing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Biopharmaceuticals Contract Manufacturing Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Biopharmaceuticals Contract Manufacturing Market, Segmentation By Service, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Biopharmaceuticals Contract Manufacturing Market

• 17.1. Germany Biopharmaceuticals Contract Manufacturing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Biopharmaceuticals Contract Manufacturing Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Biopharmaceuticals Contract Manufacturing Market, Segmentation By Service, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Biopharmaceuticals Contract Manufacturing Market

• 18.1. France Biopharmaceuticals Contract Manufacturing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Biopharmaceuticals Contract Manufacturing Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Biopharmaceuticals Contract Manufacturing Market, Segmentation By Service, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Biopharmaceuticals Contract Manufacturing Market

• 19.1. Italy Biopharmaceuticals Contract Manufacturing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Biopharmaceuticals Contract Manufacturing Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Biopharmaceuticals Contract Manufacturing Market, Segmentation By Service, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Biopharmaceuticals Contract Manufacturing Market

• 20.1. Spain Biopharmaceuticals Contract Manufacturing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Biopharmaceuticals Contract Manufacturing Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Biopharmaceuticals Contract Manufacturing Market, Segmentation By Service, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Biopharmaceuticals Contract Manufacturing Market

• 21.1. Eastern Europe Biopharmaceuticals Contract Manufacturing Market Overview
• 21.2. Eastern Europe Biopharmaceuticals Contract Manufacturing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Biopharmaceuticals Contract Manufacturing Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Biopharmaceuticals Contract Manufacturing Market, Segmentation By Service, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Biopharmaceuticals Contract Manufacturing Market

• 22.1. Russia Biopharmaceuticals Contract Manufacturing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Biopharmaceuticals Contract Manufacturing Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Biopharmaceuticals Contract Manufacturing Market, Segmentation By Service, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Biopharmaceuticals Contract Manufacturing Market

• 23.1. North America Biopharmaceuticals Contract Manufacturing Market Overview
• 23.2. North America Biopharmaceuticals Contract Manufacturing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Biopharmaceuticals Contract Manufacturing Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Biopharmaceuticals Contract Manufacturing Market, Segmentation By Service, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Biopharmaceuticals Contract Manufacturing Market

• 24.1. USA Biopharmaceuticals Contract Manufacturing Market Overview
• 24.2. USA Biopharmaceuticals Contract Manufacturing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Biopharmaceuticals Contract Manufacturing Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Biopharmaceuticals Contract Manufacturing Market, Segmentation By Service, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Biopharmaceuticals Contract Manufacturing Market

• 25.1. Canada Biopharmaceuticals Contract Manufacturing Market Overview
• 25.2. Canada Biopharmaceuticals Contract Manufacturing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Biopharmaceuticals Contract Manufacturing Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Biopharmaceuticals Contract Manufacturing Market, Segmentation By Service, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Biopharmaceuticals Contract Manufacturing Market

• 26.1. South America Biopharmaceuticals Contract Manufacturing Market Overview
• 26.2. South America Biopharmaceuticals Contract Manufacturing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Biopharmaceuticals Contract Manufacturing Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Biopharmaceuticals Contract Manufacturing Market, Segmentation By Service, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Biopharmaceuticals Contract Manufacturing Market

• 27.1. Brazil Biopharmaceuticals Contract Manufacturing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Biopharmaceuticals Contract Manufacturing Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Biopharmaceuticals Contract Manufacturing Market, Segmentation By Service, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Biopharmaceuticals Contract Manufacturing Market

• 28.1. Middle East Biopharmaceuticals Contract Manufacturing Market Overview
• 28.2. Middle East Biopharmaceuticals Contract Manufacturing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Biopharmaceuticals Contract Manufacturing Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Biopharmaceuticals Contract Manufacturing Market, Segmentation By Service, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Biopharmaceuticals Contract Manufacturing Market

• 29.1. Africa Biopharmaceuticals Contract Manufacturing Market Overview
• 29.2. Africa Biopharmaceuticals Contract Manufacturing Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Biopharmaceuticals Contract Manufacturing Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Biopharmaceuticals Contract Manufacturing Market, Segmentation By Service, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Biopharmaceuticals Contract Manufacturing Market Competitive Landscape And Company Profiles

• 30.1. Biopharmaceuticals Contract Manufacturing Market Competitive Landscape
• 30.2. Biopharmaceuticals Contract Manufacturing Market Company Profiles
  • 30.2.1. Boehringer Ingelheim GmbH Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Lonza Group Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Inno Biologics Sdn Bhd Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Rentschler Biopharma SE Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Samsung Biologics Co. Ltd. Overview, Products and Services, Strategy and Financial Analysis

31. Biopharmaceuticals Contract Manufacturing Market Other Major And Innovative Companies

• 31.1. AGC Biologics
• 31.2. ProBioGen AG
• 31.3. FUJIFILM Diosynth Biotechnologies
• 31.4. Thermo Fisher Scientific Inc.
• 31.5. Binex Co. Ltd.
• 31.6. AbbVie Inc.
• 31.7. Catalent Inc.
• 31.8. Pfizer Inc.
• 31.9. Merck KGaA
• 31.10. Pressure BioSciences
• 31.11. Novartis International AG
• 31.12. Cambrex Corporation
• 31.13. Emergent BioSolutions Inc.
• 31.14. JRS Pharma GmbH & Co. KG
• 31.15. WuXi Biologics

32. Global Biopharmaceuticals Contract Manufacturing Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Biopharmaceuticals Contract Manufacturing Market

34. Recent Developments In The Biopharmaceuticals Contract Manufacturing Market

35. Biopharmaceuticals Contract Manufacturing Market High Potential Countries, Segments and Strategies

• 35.1 Biopharmaceuticals Contract Manufacturing Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Biopharmaceuticals Contract Manufacturing Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Biopharmaceuticals Contract Manufacturing Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer